Early studies reported that the growth of 4 T1 mammary tumors was inhibited in TIM-3-deficient mice, and anti-TIM-3 monoclonal antibody (mAb) could suppress the growth of established subcutaneous EL4 lymphoma, suggesting TIM-3 as a potential target for cancer immunotherapy [20]. This evidence concerns the gene HAVCR2 and cancer.